Abstracts tagged "corticosteroids"

Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Sang Kim¹, Jean Tayar², Maria Suarez-Almazor³, Huifang Lu⁴, Yang-Zhi Zhao⁵, Margarita Divenko⁵, William Padron⁵, Emma Rodriguez⁵, Sattva Neelapu⁵, Jennifer Wang⁵, Amish Shah⁵, Nizar Tannir⁵, Don Gibbons⁵, Guillermo Garcia-Manero⁵, Hussein Tawbi⁵, Patrick Hwu⁵, Andrew Futreal⁵, Adi Diab⁵ and Roza Nurieva⁵, ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas MD Anderson Cancer Center, Houston, TX, ⁴MD Anderson, Houston, TX, ⁵MD Anderson, Houston
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
Abstract Number: 1625 • ACR Convergence 2020
Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
Zahra Rehman¹, Megan Krause¹, Jessica Newman² and Pooja Bhadbhade¹, ¹The University of Kansas Medical Center, Kansas City, KS, ²The University of Kansas Medical Center, Kansas City
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…
Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Joshua Baker¹, Mitesh Patel¹, Tuhina Neogi², Keith Robinson³, Alexis Ogdie¹ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston University School of Medicine, Boston, MA, ³Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…
Abstract Number: 1651 • ACR Convergence 2020
Efficacy and Safety of Multiple Intra-articular Corticosteroid Injections for Osteoarthritis – a Systematic Review and Meta-analysis of Randomised Controlled Trials and Observational Studies
Shazeen Ayub¹, Jaspreet Kaur¹, Michelle Hui², Michelle Hall¹, Michael Doherty³ and Weiya Zhang¹, ¹Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, United Kingdom, ²Royal Derby Hospital, Derby, UK, Derby, United Kingdom, ³Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, England, United Kingdom
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis worldwide and is becoming more prevalent with the increasing age of the population. As Intra-articular…
Abstract Number: 1652 • ACR Convergence 2020
Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA)
Justin Bucci¹, Xiaoyang Chen¹, James Torner², Michael Nevitt³, Cora Lewis⁴ and David Felson⁵, ¹Boston University, Boston, MA, ²University of Iowa, Iowa City, IA, ³University of California, San Francisco, Orinda, CA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies have questioned whether CS injections (CSI), a popular treatment recommended by guidelines, hasten progression of knee OA. A recent cohort study suggested…
Abstract Number: 1679 • ACR Convergence 2020
Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Kelly Rouster-Stevens², Marisa Klein-Gitelman³, Karen Onel⁴, Beatrice Goilav⁵, Sonia Savani⁶, Natasha Ruth⁶, Tingting Qiu⁷, Najla Aljaberi⁸, Jianghong Deng⁹, Angela Merritt⁸, Benjamin Laskin¹⁰, Anna Carmela Sagcal-Gironella¹¹, Stacy Ardoin¹², Deborah Levy¹³, Scott Wenderfer¹⁴, Bin Huang⁷, Hermine I Brunner¹⁵ and LaUNCH Project Investigators¹⁶, ¹The University of Cincinnati College of Medicine, Cincinnati, OH, ²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Charleston, SC, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Beijing Children’s Hospital, Beijing, China (People's Republic), ¹⁰Children's Hospital of Philadelphia, Philadelphia, ¹¹Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, ¹²Nationwide Children's Hospital, Columbus, OH, ¹³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, ¹⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁶LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH
Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…
Abstract Number: 1687 • ACR Convergence 2020
Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort
Monica Bray¹, Jennifer Rammel², Andrea Ramirez¹, Kristen Sexson¹, Fong Lam¹, Eyal Muscal³ and Marietta DeGuzman³, ¹Baylor College of Medicine, Houston, TX, ²University of Florida Health Jacksonville, Jacksonville, FL, ³Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…
Abstract Number: 1948 • ACR Convergence 2020
Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes
Tadashi Hosoya¹, Nikunj Shukla², Yuya Fujita³, Shiyin Yao⁴, Fitzgerald Lao⁴, Hiroyuki Baba¹, Shinsuke Yasuda⁵, Howard Cottam⁴, Dennis Carson⁴, Tomoko Hayashi⁴ and Mary Corr⁶, ¹Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ²Moores Cancer Center, University of California San Diego, San Diego, CA, ³Department of Medicine, University of California San Diego, San Diego, CA, ⁴Moores Cancer Center, University of California San Diego, San Diego, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁶Department of Medicine, University of California San Diego, San Diego
Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 0113 • ACR Convergence 2020
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines
Marielys Figueroa Sierra¹, Atefeh Vafa¹, Shu Cao², Yuanyuan Lu³, Helen Bateman⁴, John Carter¹, Yih Chang Lin², Raquel Cuchacovich¹, Marcos Maldonado⁴, Joanne Valeriano-Marcet¹ and Gabriela Montes-Rivera⁴, ¹University of South Florida, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, FL, ³Biostatistician at Graduate Medical Education Department, Tampa, FL, ⁴James A. Haley VA, Tampa, FL
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy. It is imperative to identify these patients…
Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Angela Chun¹, Lutfiyya Muhammad ² and Deirdre De Ranieri ³, ¹Lurie Children's Hospital, Chicago, Iowa, ²Northwestern University Feinberg School of Medicine, Chicago, ³Lurie Children's Hospital, Chicago, Illinois
Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium
Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Rana Masoud¹, Wajiha Jeelani ², Barbine Agbor Agbor ³, Teresa Hennon ², Brian Wrotniak ⁴ and Rabheh Abdul Aziz ², ¹Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, New York, ²Department of Pediatric Rheumatology, University at Buffalo, Oishei Children's Hospital, Buffalo, ³Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, ⁴Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, NY, USA, Buffalo
Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…
Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium
The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries
Mary Beth Son¹, Yukiko Kimura ², Kristiina Aalto ³, Lillemor Berntson ⁴, Johnathan Dallas ¹, Ciaran Duffy ⁵, Mia Glerup ⁶, Jaime Guzman ⁷, Troels Herlin ⁸, Petteri Hovi ⁹, Kimme Hyrich ¹⁰, Jens Klotsche ¹¹, Bo Magnusson ¹², Vanessa McIntyre ¹³, Ellen Nordal ¹⁴, Seza Ozen ¹⁵, Maria Jose Santos ¹⁶, Betul Sozeri ¹⁷ and Timothy Beukelman ¹⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ²Hackensack Meridian School of Medicine, Hackensack, ³Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁴Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ⁵Ottawa, Canada, ⁶Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁷University of British Columbia and BC Children's Hospital, Vancouver, Canada, ⁸Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Manchester, United Kingdom, ¹¹Berlin, Germany, ¹²Karolinska University Hospital, Stockholm, Sweden, ¹³Manchester University, Manchester UK, United Kingdom, ¹⁴Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ¹⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, ¹⁶Portugal, ¹⁷Boston, Turkey, ¹⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Takayuki Kishi¹, Takako Miyamae ², Ryoko Sakai ³, Yumi Tani ², Satoru Nagata ¹ and Masayoshi Harigai ³, ¹Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ²Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…

« Previous Page
1
…
6
7
8
9
10
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].